Technology

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

October 21, 2026 2,714 views 1 min read
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note

FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note


FDA approves GSK&039;s bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.

Tags